Medical Representative
-Achieved oral anti-diabetic market leadership in Center 2 in 2020 and maintaining it through the years till 2023 (Galvusmet)-Transferred to Hypertension portfolio since October 2023 (present)-Working on multiple therapeutic areas Hypertension, Pain and inflammation since May 2024